Search PubMed⌕ Search

Biomedical subjects

P Freitag

Publications and source records attributed to P Freitag.

At least 55 records · Page 3Linked to original sources
PubMed1998

[Sarcoma of the uterus].

Our experience with the treatment of uterine sarcoma is presented as a retrospective clinical study. The studied group is represented by 39 patients with the average age 58 years and an overall 5 year survival 36%. We recommend the abdominal hysterectomy with or without bilateral salpingooophorectomy as primary therapy. The importance of adjuvant radiotherapy and chemotherapy is discussed with a special attention to various histological types of sarcoma.

Adult↗
PubMed1996

Evaluation of the clinical safety and efficacy of iobitridol (Xenetix) in intravenous urography.

The aim of this study is to report on the clinical safety and diagnostic efficacy of iobitridol (Xenetix) in intravenous urography compared to iohexol (Omnipaque) or iopamidol (Iopamiro). A total of 120 patients underwent intravenous urography (i.v.u.); 60 received Xenetix and 60 either Omnipaque (30 patients) or Iopamiro (30 patients) according to the center where they were treated. Clinical safety was assessed by the reporting of adverse events and diagnostic efficacy was evaluated. Warmth sensation was the most commonly reported adverse event. Two cases of nausea and vomiting were reported. Concerning diagnostic efficacy, 72-74% of the i.v.u. examinations were rated good or excellent by the physician. These studies confirm that Xenetix is a suitable contrast agent for i.v.u.

Contrast Media↗
PubMed1996

[Prevalence of HPV infection and histologic correlations].

476 patients with cervical lesions were examined for HPV presence in the lower genital tract. The ViraPap/ViraType detection set was used. Prevalence of low oncogenic risk group of HPV types (LR-HPV) was 12.2% a that of intermediate and high risk group (HR-HPV) was 28.5%. It is compared with control series of 168 women undergoing interruption of pregnancy (prevalence of LR-HPV 3.0% and of HR-HPV 13.7%) and with a control series of 137 STD (sexually transmitted disease) bearers (prevalence of LR-HPV 3.6% and of HR-HPV 19.0%). HR-HPV positivity was found in 37.8% of patients with CIN I, 46.7% with CIN II and 35.3% with CIN III. 16 of 20 cases (80%) with invasive cervical cancer were HR-HPV positive. The authors confirmed a statistically significant difference of HR-HPV positivity between series of women with interruption of pregnancy, with CIN and with invasive cervical cancer. Among HR-HPV positive cases, 76.5% had CIN or invasive cancer of cervix. The role of HPV testing in clinical management of cervical lesions is evaluated and considered meaningful by authors.

Female↗
PubMed1996

[Adenocarcinoma of the uterine cervix--retrospective clinico-pathologic study].

A group of 70 female patients with adenocarcinoma of the uterine cervix treated between 1976 and 1995 at the 2nd Department of Obstetrics and Gynaecology, 1st Faculty of Medicine, Charles University and General Hospital, Prague, was evaluated retrospectively. They represented 8.6% of all patients with cervical cancer in this period. The mean age was 57.9 years and increased according to the clinical stage of disease. Some features of the patient history were similar to those of endometrial cancer. The most frequent symptom was abnormal bleeding (70%). The limited importance of praebioptic diagnostic methods was confirmed. Better treatment results were achieved by the surgical or combined treatment in comparison with radiotherapy alone. From histological types the worst results had a clear cell carcinoma. The recurrence rate was 13.4%. The overall 5-year survival was 43.1% (68% for the stage 1, 40% for the stage 2 and 22% for the stages 3 + 4). The average survival time was 96.1 months.

Adenocarcinoma↗
PubMed1995

[A comparative study of the imaging quality and picture dosage of a new conventional film-screen system for skeletal x-ray diagnosis].

PURPOSE: This paper compares a new film-screen system (FSS) called INSIGHT Skeletal Imaging System with the previously used Lanex/T-MAT G FSS. MATERIAL AND METHODS: Using a Bronder phantom, measurements were made of dose, resolution and contrast. 135 skeletal phantom images were assessed in order of quality by six observers. RESULTS: Comparable high resolution film-screen combinations (FSC) showed similar geometric resolution. Comparing high intensifying screens, the new INSIGHT Skeletal Regular FSS showed better resolution than the Lanex medium FSC. Dose reduction for the INSIGHT Skeletal Imaging FSS was 29-56%. The new FSS showed image quality similar to high resolution screens but was significantly better when using high intensifying screens. CONCLUSION: The new INSIGHT Skeletal Imaging System can replace the Lanex/T-MAT G FFS by retaining quality but reducing radiation dose by 29-56%. Using the new high intensifying FSC, images showed in addition improved film quality.

Bone and Bones↗
PubMed1995

[Diagnosis of human papillomaviruses in the lower genital tract using the ViraPap/ViraType detection kit].

The authors investigated a group of 195 patients from the Centre of Oncological Prevention for human papillomavirus (HPV) in the lower genital tract. The diagnostic set ViraPap/ViraType was used for detection. It is based on double hybridisation of viral DNA and on the use of polyclonal and monoclonal antibodies with chemoluminiscent reaction. The test was totally positive in 23.1% of women. 5.1% tests were positive in the low-risk group of viruses (LR-HPV) and 19.5% in the high risk group (HR-HPV). Precancerous lesions (CIN I-III) or invasive cancer were found in 86.7% of positive tests. In patients with CIN III 37.1% were HPV positive and all patients with invasive cancer were positive. The results support an association between CIN and HPV infections. The possible role of HPV in cancerogenesis is discussed as well as the clinical importance of their detection.

Antigen-Antibody Reactions↗
PubMed1994

[Monitoring of malignant gynecologic tumors using the immune response to lactate dehydrogenase virus antigens].

The cell mediated immunity was examined by the leukocyte adherence inhibition (LAI) test in 21 patients with CIN III and 146 patients with invasive gynaecologic malignancies before treatment and at 3-month intervals. Our own LDV antigen and organ specific antigens were used. The test was highly specific (95.1%) in comparison with a control group of healthy blood donors. The sensitivity of the test was lower (64.7-86.8%). There was no correlation with the development of disease (remission or relapse). The test in a two-year investigation does not seem suitable for monitoring of disease. Depending the nature of LDV infection, only a longer investigation extending over more years would enable further conclusions.

Antigens, Viral↗